Gut Dysbiosis Drives Breast Cancer Spread Through Bile Acid Buildup

Researchers at the University of Virginia have identified a biological pathway that helps explain why some breast cancers spread aggressively through the body—and the culprit begins in the gut. When the collection of microorganisms living in the intestines falls out of balance, a condition called dysbiosis, it loses the ability to regulate bile acids, potent molecules that normally help with digestion and metabolism. Left unchecked, these bile acids accumulate and trigger inflammation in breast tissue, creating conditions that allow cancer cells to migrate to distant organs, particularly the lungs.

The discovery centers on hormone receptor-positive breast cancer, or HR+ breast cancer, the most common form of metastatic breast cancer in women. Each year, approximately 225,000 American women receive this diagnosis. What makes HR+ breast cancer particularly dangerous is its tendency to spread early, often forming tumors in the lymph nodes and lungs before symptoms become apparent. Once the cancer has metastasized, treatment becomes far more difficult and the risk of death climbs sharply. Understanding what drives this spread has been a critical gap in cancer research.

Melanie Rutkowski, PhD, and her team at the UVA Comprehensive Cancer Center conducted experiments in laboratory mice that revealed the specific mechanism linking gut dysbiosis to breast cancer progression. They found that when the microbiome is disrupted, certain bile acids accumulate to harmful levels. These bile acids then trigger inflammatory responses in the body that essentially pave the way for cancer cells to escape the breast and establish themselves elsewhere. The researchers also observed that bile acid levels could be measured and, crucially, modified—suggesting a potential avenue for intervention.

To test whether these findings held true in human patients, the researchers examined medical records and outcomes data from women with HR+ breast cancer. They discovered that elevated bile acid levels were associated with reduced survival rates. More intriguingly, patients with metastatic disease who had been prescribed bile acid sequestrants—drugs already approved by the FDA for treating metabolic disorders—tended to live longer than those who had not received these medications. While the researchers emphasize that more rigorous studies are needed to prove the drugs are directly responsible for the survival benefit, the pattern is encouraging enough to warrant further investigation.

Rutkowski and her colleagues propose two potential therapeutic approaches. The first would involve replenishing the specific bacteria in the gut that naturally regulate bile acid composition, essentially restoring the microbiome to a healthier state. The second would use existing FDA-approved bile acid sequestrants to chemically reduce bile acid levels in the body. Both approaches could theoretically prevent the inflammatory cascade that enables metastasis. The fact that bile acid sequestrants are already approved and well-tolerated by patients makes them particularly attractive candidates for clinical trials.

The next phase of research will test whether these bile acid-suppressing drugs can prevent breast cancer from spreading in the first place, rather than simply extending survival after metastasis has occurred. If successful, this could establish a new preventive strategy for the hundreds of thousands of women diagnosed with HR+ breast cancer each year. The work represents the kind of mechanistic discovery that can reshape how doctors approach cancer prevention and treatment—moving from managing advanced disease to stopping it before it takes hold.